Total Liabilities Equity - Intercept Pharmaceuticals Inc (F:I4P) - Alpha Spread
I

Intercept Pharmaceuticals Inc
F:I4P

Watchlist Manager
Intercept Pharmaceuticals Inc
F:I4P
Watchlist
Price: 17.52 EUR Market Closed
Market Cap: 732.8m EUR
Have any thoughts about
Intercept Pharmaceuticals Inc?
Write Note

Intercept Pharmaceuticals Inc
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Intercept Pharmaceuticals Inc
Total Liabilities & Equity Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Total Liabilities & Equity Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
I
Intercept Pharmaceuticals Inc
F:I4P
Total Liabilities & Equity
$393.2m
CAGR 3-Years
-13%
CAGR 5-Years
-7%
CAGR 10-Years
9%
Abbvie Inc
NYSE:ABBV
Total Liabilities & Equity
$141.9B
CAGR 3-Years
-1%
CAGR 5-Years
20%
CAGR 10-Years
17%
Gilead Sciences Inc
NASDAQ:GILD
Total Liabilities & Equity
$53.6B
CAGR 3-Years
-8%
CAGR 5-Years
-3%
CAGR 10-Years
6%
Amgen Inc
NASDAQ:AMGN
Total Liabilities & Equity
$90.9B
CAGR 3-Years
15%
CAGR 5-Years
9%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Liabilities & Equity
$20.1B
CAGR 3-Years
18%
CAGR 5-Years
23%
CAGR 10-Years
25%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Liabilities & Equity
$36.1B
CAGR 3-Years
19%
CAGR 5-Years
22%
CAGR 10-Years
26%

See Also

What is Intercept Pharmaceuticals Inc's Total Liabilities & Equity?
Total Liabilities & Equity
393.2m USD

Based on the financial report for Sep 30, 2023, Intercept Pharmaceuticals Inc's Total Liabilities & Equity amounts to 393.2m USD.

What is Intercept Pharmaceuticals Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
9%

Over the last year, the Total Liabilities & Equity growth was -30%. The average annual Total Liabilities & Equity growth rates for Intercept Pharmaceuticals Inc have been -13% over the past three years , -7% over the past five years , and 9% over the past ten years .

Back to Top